文献速递淋巴瘤

间变性大细胞淋巴瘤中IL-1R通路的分析与治疗靶向

Analysis and therapeutic targeting of the IL-1R pathway in anaplastic large cell lymphoma.
PubMed 文献 · Blood · 2023-01-01

研究对ALK阳性(ALK+)和原发皮肤(pC)ALK阴性(ALK-)间变性大细胞淋巴瘤(ALCL)进行全基因组CRISPR文库筛选,发现IL-1R炎症通路以自分泌IL-1α方式支持pC ALK- ALCL存活,该通路由A20功能缺失突变促进并经非蛋白水解性泛素化网络调控,可增强JAK抑制剂敏感性,JAK2/IRAK1双重抑制剂pacritinib在细胞系和异种移植小鼠模型中表现出强活性。

要点

  • 全基因组CRISPR筛选揭示IL-1R通路支持pC ALK- ALCL细胞存活。
  • IL-1α以自分泌方式激活IL-1R通路,对促肿瘤炎症反应的诱导和维持至关重要。
  • A20功能缺失突变促进IL-1R通路过度激活,该通路增强JAK抑制剂敏感性。

核心结论

  • 研究揭示了IL-1R通路在pC-ALCL中的重要作用,并为开发新型治疗策略提供了机会。

研究设计与样本

  • 对ALK+和pC ALK- ALCL进行全基因组CRISPR文库筛选,并在pC-ALCL细胞系和原发病例中验证。

主要发现

  • IL-1R通路以自分泌IL-1α方式激活,对pC-ALCL细胞系和原发病例中促肿瘤炎症反应的诱导和维持至关重要。
  • A20功能缺失突变促进所分析pC-ALCL细胞系中IL-1R通路过度激活,该通路受非蛋白水解性蛋白泛素化网络调控。
  • IL-1R通路在缺乏STAT3功能获得性突变或ALK易位的ALCL中促进JAK-STAT3信号激活,并在体外和体内增强这些肿瘤对JAK抑制剂的敏感性。
  • JAK2/IRAK1双重抑制剂pacritinib在IL-1R通路过度激活的pC ALK- ALCL细胞系和异种移植小鼠模型中表现出强活性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anaplastic large cell lymphoma (ALCL), a subgroup of mature T-cell neoplasms with an aggressive clinical course, is characterized by elevated expression of CD30 and anaplastic cytology. To achieve a comprehensive understanding of the molecular characteristics of ALCL pathology and to identify therapeutic vulnerabilities, we applied genome-wide CRISPR library screenings to both anaplastic lymphoma kinase positive (ALK+) and primary cutaneous (pC) ALK- ALCLs and identified an unexpected role of the interleukin-1R (IL-1R) inflammatory pathway in supporting the viability of pC ALK- ALCL. Importantly, this pathway is activated by IL-1α in an autocrine manner, which is essential for the induction and maintenance of protumorigenic inflammatory responses in pC-ALCL cell lines and primary cases. Hyperactivation of the IL-1R pathway is promoted by the A20 loss-of-function mutation in the pC-ALCL lines we analyze and is regulated by the nonproteolytic protein ubiquitination network. Furthermore, the IL-1R pathway promotes JAK-STAT3 signaling activation in ALCLs lacking STAT3 gain-of-function mutation or ALK translocation and enhances the sensitivity of JAK inhibitors in these tumors in vitro and in vivo. Finally, the JAK2/IRAK1 dual inhibitor, pacritinib, exhibited strong activities against pC ALK- ALCL, where the IL-1R pathway is hyperactivated in the cell line and xenograft mouse model. Thus, our studies revealed critical insights into the essential roles of the IL-1R pathway in pC-ALCL and provided opportunities for developing novel therapeutic strategies.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Song Z, Wu W, Wei W, et al. Analysis and therapeutic targeting of the IL-1R pathway in anaplastic large cell lymphoma. Blood. 2023. PMID: 37339580. doi:10.1182/blood.2022019166

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。